References
Kumar N, Abboud H (2019) Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler 25(8):1079–1085
Rekhi E, Pryce A, Sohal M et al (2016) CNS demyelination in patients on nilotinib treatment for CML. J Neurol Neurosurg Psychiatry 87(12):e1
Rimkus CM, Schoeps VA, Boaventura M et al (2021) Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Mult Scler Relat Disord 55:103146
Judge C, Moheb N, Melinosky C (2019) Nilotinib-associated demyelinating disease: case report. Neurol 92(Supplement1):P.22-093
Liu Y, Wang Z et al (2011) Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 55:612–625
Betsholtz C (2004) Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15(4):215–228
Wilson H, Scolding N, Raine C (2006) Co-expression of PDGF a receptor and NG2 by oligodendrocyte precursors in human CNS and multiple sclerosis lesions. J Neuroimmunol 176:162–173
Zeitelhofer M, Adzemovic M et al (2020) Blocking PDGF- CC signaling ameliorates multiple sclerosis- like neuroinflammation by inhibiting disruption of the blood–brain barrier. Sci Rep 10(1):22383
Nachliely M, Trachtenberg A et al (2019) Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. J Steroid Biochem Mol Biol 188:8–16
Xu JG, Cheng Q et al (2022) Effect of dimethyl fumarate (DMF) on T-cell acute lymphoblastic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30(1):1–5
Maeta T, Sato T et al (2022) Dimethyl fumarate induces apoptosis via inhibiting NF-κB and STAT3 signaling in adult T-cell leukemia/lymphoma cells. Anticancer res 42(5):2301–2309
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
This paper was approved by the Ethical committee from the blinded manuscript.
Informed consent
Informed consent was received from patient.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Erturul, E., Kocer, B., Gokce, S. et al. CNS demyelination associated with nilotinib. Neurol Sci 44, 3335–3339 (2023). https://doi.org/10.1007/s10072-023-06827-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-023-06827-4